Abstract
Introduction
At least four forms of fungal infeetion of the sinonasal traet have been reeognized. Two are nonin vasive: allergie fungal rhinosinusitis and fungus ball (myeetoma).The other two are tissue-in vasi ve: ehronie invasive (indolent) fungal sinusit is and aeute invasive (fulminant) fungal sinus itis.
One form of aeute invasive sinu sitis eaused by fungi of the order Mueorales is known as mucormy cosis,' Mueormyeosis is a rapidl y progressive infeetion that usually develops in pat ients who are metabolieally or immun ologically compromised. Left untreated, it is rapidly fata!.
Muc ormycosis elas sieally involves the nasaI mueo sa with invasion of the sinuses, orb it, and brain. ' The eausative organisms are memb ers of the family Mue oraeeae, whieh belongs to the order Mueorales of the elass Zygomyeetes. They are saprophytes eommonly found in soil, deeomposed vege tation, and in the healthy human respi ratory and digestive traets, and their distribution is worldwide. ' Mueormyeosis ean manifest as one ofsix different elinieal syndromes; it appears in rhinoeerebral, pulmonary, gastrointestinal, central nervous system, subeutaneous, and disseminated forms. Rhinoeerebral mucormycosis (RCM) is the most common of these forms, and it is subdivide d into three subtypes : rhinomaxi llary, rhinoorbital, and rhinoorbitocerebral.v The elassifieation of RCM has no effeet on patient eare, however, beeause the mainstays of therapy are similar regardl ess of the site of extensio n. The keys to management are reversal of the und erlying eause of immunoeompromise, be it diabetie ketoaeidosis or neutrop enia, and appropriate antifungal therapyand surgieal debridement of the involved tissues.'?
Patients usually present with headaeh e, rhinorrhea, or epistaxis along with black nasal or oral masses. Anesthesia preeedes the development of the eharaeteristie tissue necrosis." Progression ean lead to orbital cellulitis, orbital apex syndrome, eave mous sinus thrombosis, and eventually fatal involvement of the central nervous syste m. The diagnosis is made histologieally because it is invasion and tissue reaction rather than the mere prese nee of such ubiq uitous fungi that charaeterizes the disease. Culture is used to identify the specific species . ' In this artiele, we deseribe a elassie prese ntation of rhinoo rbita l mue orm ycosis. This case illustrates the importanee of maintaining a high index of suspicion in making an early diagnosis.
Management of the ENT patient is complex
• In one study, up to 40% of the patients seen in an ENT practice may be suffering from IgE mediated hvpersensitivitv'
• In another recent study, testing of patients for atopic allergy revealed that more than 60% of patients on anti-histamine therapy were not allerqic"
In-vitro testing for specific IgE is a cost effective and patient friendly way to enhance allergy diagnosis and improve patient management; testing your patients in your offic e allows you to accurately diagnose and manage allergic patients within your practice . 
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Iymphoblastic leukemia, for which he was placed on a chemotherapeutic regimen. After I week of chemotherapy, the patient developed severe neutrapenia with fever, mucositis, and generalized lassitude, which necessitated intravenous braad-spectrum antibiotic therapy as weil as empiric antifungal treatment with f1uconazole. After a few days of this treatment in the medical ward, the patient began to exhibit recurrent mild left-sided nasal bleeding, left facial edema, excessive lacrimation from the left eye, and periorbital swelling. An ophthalmologist who was consulted noticed mild praptosis with edematous, congested conjunctiva and ophthalmoplegia; however, the eye fundus and vision were norma!. A preliminary diagnosis of orbital cellulitis was made, and urgent computed tomography (CT) was requested. CTshowed partial opacification ofthe left maxiliary, ethmoid, and frontal sinuses with nasal mucosal swelling and an obvious extension of the inflammatory process to the inferomedial orbital wall , which displaced the globe anterolaterally ( figure I ) . But no clear collection or bony erosion was noticed, and the brain was intact. Further examination by an otolaryngologist revealed that the most striking feature of this disease was the presence of black necrotic tissue (eschar) in the left nasal cavity and a patchy black discoloration of the hard palate in two areas, each 5 mm in diameter, opposite the molars (figure 2). No ulceration was evident.
Within 24 hours, the patient underwent urgent endoscopic debridement of the eschar on the lateral nasal wall under local anesthesia. Debridement spared the viable nasal and sinus mucosa, which was congested and edematous. The orbit was not penetrated. The removed material was sent for fungal culture and histopathologic study ( figure 3 ). Both studies confirmed the diagnosis of a fungal infection consisterit with mucormycosis.
The next day, intravenous amphotericin B at 1.5 mg/kg/ day was started along with saline nasal irrigation. Within a few days, the patient's fever, orbital cellulitis, proptosis, and palatal necrosis had almost resoived. Treatment was continued for 6 weeks followed by further courses of chemotherapy for the underlying Iymphoma. At 24 weeks following the last antifungal treatment, the patient exhibited no evidence of further infection.
Fungal culture. Processing of the nasa I specimen for mycology was carried out in the manner described by TajAldeen et al.?The necrotic tissue specimen isolated from the nose was examined for evidence offungal invasion. The tissue was cut into small pieces in sterilized saline and then ground for 30 seconds in a seal ed plastic bag placed in a Stomacher Lab Blender (model No. 80). A drop ofthe homogenate containing the small pieces oftissue was viewed in lactophenol cotton blue and in a 30% KOH solution and visualized under light microscopy at a magnification of 400 . Branched, nonseptate, broad hyphae were evident in this preparation. The remainder of the homogenate was cultured onto two sets ofthree media: Sabouraud dextrose agar (SDA) pius 40 U/ml of streptomycin and 20 U/ml of penicillin (SDA + SP), SDA without antibiotics, and a brain-heart infusion pius 40 U/ml of streptomycin and 20 U/ml of penicillin. One set of plates was incubated at room temperature and the other at 37°C.
Fungal colonies appeared in 2 days. Examination of the fungus revealed a pure growth of Rhizopus oryzae Went and Prinsen Geerlings. The fungus was further subcultured .on SDA + SP slants and stored in screw-capped tubes.
The identification of R ory zae was confirmed by the Centraalbureau voor Schimmelcultures Fungal Biodiversity Center in Utrecht ,The Netherlands.All investigations were perfonned under safety conditions (class II) in order to RHINOCORT AQUA is indicated for the management of nasal symptoms of seasonal and perennial allergic rhinitis in aduits and children 6 years of age and older.
The overall incidenee of adverse events with RHINOCORT AQUA was similar to that observed with vehicle placebo . In c1inical trials, commonly reported adverse events with RHINOCORT AQUA versus vehicle placebo were epistaxis (8% vs 5%), pharyngitis (4% vs 3%), bronchospasm (2% vs 1%), coughing (2% vs < 1%1. and nasal irritation (2% vs < 1%).
* The recommended starting dosage for RHINOCORT AQUA is 1 spray per nostril once daily (64-mcg total daily dose), with individualized dosing up to 256 mcg for aduits and 128 mcg for children aged 6 to 12 years . Prescribe the lowest amount necessary for contral of symptoms. A simil aradverseevent prolile was observed in Ihe subg roup of pedi atrie pat ients 6 10 12yea rs 01age. Two to threeper cent (2·3%)of pat ienlsinclinical trial s di seonlinued beeauseof adverse evenls. Systemie eortieosleroid side eHeets werenot reported during eontrolled el inieal studies wilh RHINOCORTAOUA Nasal Spray. II reeom· mended dosesare exeeeded,however , or it individualsarepartieul arly sensiti ve, symploms 01 hyper eortiei sm, ie, Cushing's Syndrome, eould oeeur. Rareadverse event s report ed Irom post-market ing experience inelude: nasal septum pertorat ion, pharynx disorders (throat irrilation, throatpain, swolien throat , bu rni ng throat. and itehy throat), angioedema, anosmia, and palpi talions. Cases of growth suppressionhave been reported lor intranasal eorti eosteroidsineluding RH INOCORT AOUA Nasal Spray (seePRECAUTIONS, Pediat rieUse), DOSAGE AND ADMINISTRATION The reeommended starting dosefor adultsand ehildren 6yea rs01 age andolderis64meg perday administe redas onespray per noslril 01RH INOCORT AOUANasalSpray 32 megonee dail y. Themaximum recommended dose for adults (1 2years01 age andolder) is256 meg per day administered aslourspray spernostril oneedail y ofRHINOCORT AOUA Nasal Spray 32megand themaximumreeommended dose forpediatr icpati ents (<1 2yearsofage)is 128meg perdayadminisIeredas two spray spernostril onee daily 01 RHINOCORT AOUA Nasal Spray 32 meg (see HOW SUPPUED) Ind i vi dual iza~a n of Dosase: II is all'lays desirabl etotitraleanindividual patient tothe minimum effeetive doseto redueethepossibllity of side elfeets. HOW SUPPlIED RHINOCORT AOUA Nasal Spray 32 meg is availabl e in agreen eoated gl ass bollle wilh a metere d·dose pump sprayand a green protection eap. RH INOCORT AOUA Nasal Spray 32 meg provides 120 meteredsprays aft erinit ialpriming; net lill weight 8.6 9 TheRHIN OCORT AOUA Nasal Spray 32 mcg bottle has been lilled wit h an me ss to aeeommodate the priming aetivity. The bottl e should be disearded after 120 sprays following inilial priming, sinee the amount of budesonide dellvered per spray therealler may be substantiallylessthan thelabeieddose. Eaeh spray delivers32meg01 budesonidetoIhe patient. In ellnieal studies with budesonide administered intranasally, the development of loealized inl eel ionsof thenoseandpharynxwilh Gandidaalbieans has oeeurred only rarely. When suchan inleetion develops, il may requiretreatment wi th appropriateloeal or systernietherapy and diseonli nua· lionoftreat ment wi lh RHINOCORT AOUA NasalSpray. Patienlsusing RHINOCORT AOUA NasalSpray ove r seve ral months or longer should be exami ned periodieall y lor evidenee of G andidainleetion or other signs 01 adverse eHeetsonIhenasalmueosa. RHINOCORT AOUA NasalSpray shouldbeusedwi theaution, il at all.inpatientswi th aetive orquieseenltubereulous inleetion, untreat edlungal, bael erial ,orsystemieviral inl eetions,oroeular herpes simplex. Beeause of the inhibitory eHeet of eortieosteroids on wound heali ng, pat ients who have experienced reeent nasalseptal ul eers,nasalsurgery, or nasaI trauma shouldnoi useanasai eorti eosteroid until healing has oeeurred. Hepal iedysfuneti on influeneesthepharmaeokinetiesofbudesonide, similartotheelfeet onothereorti· eosteroids, wilh aredueed elimination raI eand inereased systemie availability (seeCUNICAL PHARMACOLOGY, Speeial Populati ons in lull Preseribing Inf ormati on), InfarmaHon for Patients: Pat ients being treated with RHI NOCORT AOUANasalSpray should reeeivethe foll owinginformation and instrueti ons. Pat ients who areon immunosuppressantdosesofeortieosteroidsshoul dbe warnedtoavoidexposuretoehieken pox ormeasl esand, it exposed, toobtainmedicaladviee. Pal ientsshoulduseRHINOCORT AOUANasalSpray at regul ar int er val ssi nee itselfeetiveness depends onilsregul ar use(see DOSAGE ANDADMINISTRATIONintuliPreseribingInformali on). An improvement in nasalsymploms may be noted in patients wi lhi n 10hours of first using RHINOCORT AOUA NasalSpray, This timetoonset is supported byan envi ronmentalexposure unit study inseasonal allergie rhini tis patientswhi ehdemonstraledIhat RH INOCORT AOUA NasalSpray led to astatistiealiy signifieant improvemenlin nasalsymptoms eompared 10 plaeebo by 10hours. Furthersupporteomes lrom aclinicalstudy 01 patients wilh perennialallergie rhinitiswhieh demonstrated astalistieallysignifieant improvement in nasalsymptoms for both RHINOCORTAOUANasalSprayand lor theaetive eomparator (momelasone luroat e) eompared to plaeebo by 8 hours. Onsetwasalsoassessedinthi s study with peak nasalinspiral oryHowrat eandthi sendpoinl tail ed toshow effieaey foreither aetive treatment. Although statisliealiysignilieant improvements innasalsymptoms eompared to pl aeebowerenoted wilhi n 8-10 hours in these sludies, about one hallto 11' 10 thirds 01 the ultimate eli nieal improvemenl wil h RHINOCORTAOUANasalSpray oeeurs over thelirst1-2days, and maximumbeneflt maynoi be aehieved untilapproximately 2 we eks aft er ini tiation 01 treatment.Initial assessment for responseshould be madeduring this time frameand periodieall y until thepal ienl' s symptoms arestabilized. Thepatientshould take Ihemedieation as direeted andshouldnot exeeed the preseri bed dosage. Thepatientshouldeonlaetthephysieian il symploms do notimprove aller two weeks, or if Ihe eonditionworsens. Patients whoexperience reeurrent episodes ofepistaxi s (nose bleeds) or nasal septum diseomfortwhiletaking Ihis mediealion should eontael lheir physi eian. For properuse01 this unit and10 at/ai n maximum improvement,thepali entshould read andfoll owthe aeeompanying patient instruelions ear efully. It is important 10 shake the botlle weil belore eaeh use. The RHINOCORTAOUANasalSpray 32meg bollle hasbeen lilled wi lhan m ess 10aeeommodal ethe primingaetivity, Thebollle should bedisearded after 120sprays followinginitial priming, sinee the amouni of budesonidedeliv· ered per spray thereaft er may be substantialiy less than Ihe label ed dose, Oo noI transfer any remaining suspension toanother bollle, Drug Interaetians: The mainrout eofmetabolism 01budesonide,asweil asother eortieosleroids. is via eytoehrome P450 (CYP)isoenzyme3A4 (CYP3A4). Al ter oral administralionofketoeonazole,apotent inhibitorof CYP3A4 ,themeanplasma eoneenlrat ionof orally admi nisteredbudesonideinereasedby morethan seven·fol d. Coneomilant administration of other known inhibitors ofCYP3A4 (eg,itraeonazole, elar ith· romyein, erylhromyein, el e,) may inhibit themetaboli sm of, and inereasethe systemie exposureto, budesonide (see WAR NINGS andPRECAUTIONS, General). Careshoul d be exe reisedwhen budesonideiseoadminisleredwith long-Ierm ketoeonazoleand other known CYP3A4 inhibitors. Omeprazole, an inhibilor otCYP2C19,di dnothave elfeets onthepharmaeokinet ies of oral budesonide, whi leeimetidine, primarily an inhibi tor 01 CYP 1A2, eaused a sllght deereasein budesonideelearanee andeorrespondi ng inerease in Itsoralbioavailabillty. Cardnosenesis, Mutagenesis, Impairment of FerHlity: In atwo'year study in Sprague·Dawley rats, budesonide caused a slat islieall y signifieantinerease intheincidenee 01gli omas inthemalerat s reeei vingan oral doseof 50 meglkg (approximately twice themaximumreeommended dailyinlranasal doseinadults andehildrenonameg/m 2 basis).
No lumorigenieity was seen in maleandfemale ralsal respeetiveoral doses upto25 and 50 meglkg (approximal ely equal to and two limes the maximum reeommended daily intranasal dose in adults and ehildren on a meg/m 2 basis, respeelively). Intwo addi tional two'yearsludies inmaleFischer and Sprague·Dawley rats, budesonide eaused no gliomas al an oral dose 0150 meg/kg(approxi mately twice the maximum reeommended dail y intranasal dosein adults and ehildren ona meg/m 2 basi s). However, in maleSprague·Dawley rats, budesonide eaused astatistieally si gnilieant inereasein the incideneeof hepatoeell ulartumors atan oraldose01 50 meglkg (approximat ely twicethemaxi mumreeommended dailyintranasal doseinadultsandehildrenonameg/m 2 basis). Theeoneurrent rel erenee eortieoster oids(prednisolone andIriameinoloneaeetonide) inIhesetwostudiesshowed similarlindings. Ina91 ·week study inmi ee, budesonide eausednoIreatment'relat ed eareinogenieity at oraldoses upto200 meg/kg (approxi mately3times themaximum reeommendeddailyinlranasal dosein adultsand ehildren on a meglm2 basis). Budesonide wa s not mutagenie or elastogenie in six di lferenl tesl systems: Ames minimize contamination with airbome genns.
Histopathology. In addition to the routine hematoxylin and eosin (H&E) staining, the tissue sections were stained for funga l elements. Two histologic stains-periodic acid -Schiff (PAS) and Grocott-Gomori methenaminesilver stains-were used to visualize the tissue and the funga l pathogen. A carefu l microscopic examination of the debrided nasal mucos a on PAS staining demonstrated widespread tissue necrosis that was heavi ly infiltrated by broad, ribbon-like, nonseptate or barely septate hyphae, whic h were haphazardly branc hed or branched at right ang les ( figure 4, A) . Histology of the tissue stained by Grocott-Gomori methenamine-silver revea led that the fungal hyphae had invaded the blood vesseis, a characterist ic feature of muconnycosis ( figure 4, B) .
Discussion
Muconnycosis has certainly eamed its designation as the most acutely fatal fungal infect ion known to man. JO Muconnycosis is also known as zygomycos is, hyphomycosis , phycomycosis, esvsfulminant funga l sinusitis. The infection can involve the lungs , central nervous system, gastrointestinal tract, and skin, but it is probab ly best known for its rhinoc erebra l presentation, which usually originates in the nose and sinuses and eventually extends to the orbit and brain."
Upper airwa y muconnycosis was first described in 1885 by Paltauf, who called it mycosis mu corina." In 1943, Gregory et al reported the more typical finding s ofadvanced RCM in 3 patients with fatal diabetic ketoacidosis.!' Cure of the disease was first reported in 1955 by Harris.!'
Mucormy cosis refers to any fung al infection of the order Mu corales. Most pathogenic species are members of the family Mucoraceae, which incl udes the genera Absidia, Mucor , Rhizomucor, and Rhizopus . R ory za e is the predominant pathogen, acco untin g for 60% of all forms of mucormycosis and 90% of all cases of RCM.lo.J5As-sess ment of the exact causative species is limited by the lack offungal culture infonnation in most of the reported cases.r "-"
Regardless of the causative agent, the clinical presentation and management are the same . Mycologic evaluation of the infected tissue specimen in our patient revealed the growth of R ory za e. Although the responsible fungus HILAL,TAJ·ALDEEN , MIRGHANI can be isolated in the nose ofhealthy subjects, it can tum pathogenic in patients with immunologic or metabolic compromise. Among the recognizable risk factors for the development of RCM are poorly controlled diabetes, hematologic mali gnancies, acquired immunodeficiency syndrome, severe burns , renaI diseases, malnutrition, iatrogenic immunosuppression after organ transplantation, and deferoxamine therapy.vv" Few cases have been reported in patients who did not have a predisposing factor. 5 ,18 At least two factors favored the diagnosis ofRCM in our patient: hematologic malignancy in relapse and chemotherapy. RCM begins with colonization of the nasal mucosa by airbome spores. In normal hosts, a phagocytic response to colonization prevents infection . In immunocompromised hosts, on the other hand , the response is suboptimal and germination ensues." Mucorales hyph ae have a predilection for growth into arteries and the Iymphatic system. These fungi also invade the nerves, fatty tissues , and bones; muscles are usually spared . Angioinvasion by the hyphae produces a fibrin reaction and the development of"mucor thrombi ," which occlude the arteries and lead to ischemia, infarction, and consequent formation ofthe black necrotic eschar of the skin and mucosa that is characteristic of RCM. Vascular occlusion prevents systemic antifungal agents from reaching their targets , and ischemi a favors the development ofacidotic tissue , which is ideal for fungal growth .t-!" The infection spreads rapidl y to adjacent sinuses and the orbit and continues into the cranium via the ethmoid bone or orbital vessels ." In our patient, the orbital manifestation occurred at almost the same time as did the nasal symptoms, yet the patient did not experience intracranial spread; hence , "rhinoorbital" mucormycosis was the most acceptable terminology.
Feveris themost common early symptom (44% ofcases) , followed by nasal ulceration or necrosis, periorbital or facial swelling, and decreased vision , each of which occurs in approximately 33% of cases.I-" Ultimately, 80% of patients develop a necrotic lesion on either the nasal or oral mucosa. " In addition to proptosis, our patient developed all of these signs and symptoms at about the same time. Other less frequent features include facial pain or numbness, nasal congestion or discharge, headache, ophthalmoplegia, anesthesia over the cheek, and cranial polyneuropathy, which may be consistent with orbital apex syndrome.v-"
When the clinical picture includes the presence of sinusitis with black discolo ration in the nose and palate in addition to a predisposing factor, a diagnosis of RCM should be high ly suspected. Even so, a tissue biopsy is necessary to confirm the diagnosis. 2, 5, 7 Invasive hyphae can be seen as ribbon-like, 10-to 20-microns-wide, haphazardly branched organisms with little or no septat ion. The fungus can be seen on H&E , PAS, and Grocott-Gomori methen amine-silver staining, and it is easily differentiated 560 from Aspergillus organ isms , which have a thinner wall, characteristic regular septation , and brush-like branching. In our patient, PAS and Grocott-Gomori methenamine-silver staining readily demonstrated the fungus.
Blood vessel invasion with thrombosis is a peculiar feature of RCM , and it contributes to its necrotic, ischemic appearance. Inflammatory response is variable and depends on the host's immune status. Edema and necrosis with accumulation ofneutrophils, plasma cells, and giant cells are usually seen." Direet nasal smear examination and culture for fungus help to identify the specific species (e.g., R oryzae), but a lack offungal growth does not exclude the disease."
Radiographic findings are helpful in assessing the different stages ofthe disease rather than in making a definitive diagnosis because the radiographic features may be indistinguishable from those of simple rhinosinusitis. In fact, during the early stages of RCM , imaging features may even be norma!. It is only late in the progression of the disease that bony erosion will appear." In our patient, various degrees of mucosal thickening within the nose and sinuses were noticeable and the appearance oforbital extension was similar to that seen in bacterial orbital eellulitis , yet the bony framework was intact.
The treatment ofRCM involves a combination ofsurgical and medical modalities pIus correction of the underlying medical problem ifpossible. The timing ofsurgery is very crucial; surgery should be instituted without delay once the condition is diagnosed." Several surgical procedures have been described in the literature . They range from the simple to the complex-debridement of the necrotic mucosa; Caldwell-Luc surgery; ' medial maxillectomy, ethmoidectomy, and sphenoidotomy; and radical maxillectomy with orbit al exenteration. Both endoscopic and open approaches have been described, in both single and multiple stages. ' The standard medical therapy for RCM is amphotericin B in a dose of 1.0 to 1.5 mg/kg/day for a period of several weeks to several months , depending on the clinical response and the degree of the drug's side effects , especially nephrotoxicity.3-5.7.8 Less toxic forms ofamphotericin B-such as liposomal amphotericin B, colloidal dispersion amphotericin B, and amphotericin B lipid complex-may be more safe." In our patient, early debridement of the eschar followed by intravenous amphotericin B within 24 hours appeared to be very effective in controlling RCM , while chemotherapy simultaneously controlled the lymphoma. Other promising therapeutic modal ities worth mention include hyperbaric oxygen therapy? and nasally nebulized amphotericin B.8.20
The prognosis ofRCM appears to depend primarily on two factors: early diagnosis and resolution ofthe predisposing condition. Survival has been positively correl ated with the time of diagnosis and initiation of treatment. 
